These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Dowson AJ, Almqvist P. Curr Med Res Opin; 2005 Sep; 21 Suppl 3():S13-7. PubMed ID: 16083519 [Abstract] [Full Text] [Related]
3. Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany. Diener HC, Gendolla A. Curr Med Res Opin; 2005 Sep; 21 Suppl 3():S18-24. PubMed ID: 16083520 [Abstract] [Full Text] [Related]
6. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Sheftell FD, Dahlöf CG, Brandes JL, Agosti R, Jones MW, Barrett PS. Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814 [Abstract] [Full Text] [Related]
9. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Chen LC, Ashcroft DM. Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569 [Abstract] [Full Text] [Related]
16. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study. Gawel M, Aschoff J, May A, Charlesworth BR, REALIZE Study Team. Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607 [Abstract] [Full Text] [Related]